DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Bergh JCS, Andersson A, Bjohle J. et al.
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?.
J Clin Oncol 2019;
DOI: 10.1200/JCO.2019.37.15_suppl.501.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.